J.P. Morgan Initiates Coverage on Cephalon (CEPH)
More News related to CEPH
- Alkermes (ALKS) Regains Full Commercial Rights to VIVITROL(R) in US; Updates FY09 Outlook
- Cephalon (CEPH) and Eurand (EURX) File Infringement Suit Against Mylan (MYL) and Barr Pharma (BRL)
- Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
- Cephalon (CEPH) and ImmuPharma Sign $15 Million Option Agreement for Late-Stage Experimental Lupus Medication
- Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
More News related to New Coverage
- Raymond James Starts Millicom (MICC) at Strong Buy
- Stifel Nicolaus Starts City National (CYN) at Hold
- Stifel Nicolaus Starts eHealth (Nasdaq: HLTH) with a Buy
- Wasserman & Associates initiates coverage on American Physicians Service Group (AMPH) with a Buy
- Jesup & Lamont Initiates Coverage on AutoZone (AZO) with a Hold.
J.P. Morgan initiates coverage on Cephalon (Nasdaq: CEPH) with an Overweight rating.
Cephalon, Inc. is an international biopharmaceutical company engaged in the discovery, development and marketing of products to treat human diseases.
Related Categories
New CoverageStocks Mentioned
+2.74Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
